Gingivitis Drug Pipeline Analysis Report 2025

Gingivitis is a common, mild form of gum disease characterized by inflammation, redness, and bleeding of the gums, affecting 40%-70% of patients during the gestational period. It accounts for a significant portion of oral health issues globally. There is a high unmet clinical need for better therapies, as current treatments primarily involve oral hygiene practices and antiseptic mouthwashes. Emerging gingivitis drug candidates, including anti-inflammatory agents and antimicrobial therapeutics, offer promising potential. The growing focus on preventive dental care is likely to support pipeline growth, driving innovation and improving outcomes in the coming years.

Report Coverage

The Gingivitis Drug Pipeline Insight Report by the publisher gives comprehensive insights into gingivitis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for gingivitis. The gingivitis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The gingivitis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with gingivitis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to gingivitis.

Gingivitis Drug Pipeline Outlook

Gingivitis is a mild, reversible form of gum disease caused by plaque accumulation along the gumline. It occurs when bacteria in plaque trigger gum inflammation, leading to redness, swelling, and bleeding, especially during brushing or flossing. Poor oral hygiene is the primary cause, but smoking, diabetes, and hormonal changes can also increase the risk of gingivitis.

Gingivitis treatment involves removing plaque and reducing inflammation. Professional dental cleanings, including scaling and root planing, help eliminate tartar buildup. Daily oral hygiene, such as brushing twice, flossing, and using an antiseptic mouthwash, is crucial. Dentists may prescribe antibiotics for persistent infections. Lifestyle changes, like quitting smoking and maintaining a healthy diet, also support recovery.

Gingivitis Epidemiology

Gingivitis, an early stage of periodontal disease, commonly affects 40%-70% of individuals during the gestational period. In the United States, about 4 in 10 adults aged 30 and older experience periodontitis. In Japan, 8.6 million people received treatment for gingivitis in 2020. In India, the prevalence of periodontal disease is 51%, highlighting the growing need for effective treatments.

Gingivitis - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of gingivitis drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Biologics
• Peptides
• Monoclonal Antibodies
• Natural Compounds

By Route of Administration

• Oral
• Parenteral
• Others

Gingivitis - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total gingivitis clinical trials.

Gingivitis - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the gingivitis pipeline analysis include small molecules, biologics, peptides, monoclonal antibodies, and natural compounds. The gingivitis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for gingivitis.

Gingivitis Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the gingivitis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed gingivitis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in gingivitis clinical trials:

• Colgate Palmolive
• GlaxoSmithKline
• Lion Corporation
• Noveome Biotherapeutics
• Procter and Gamble
• Biomedical Development Corporation
• Rowpar Pharmaceuticals, Inc.
• Gaba International AG

Gingivitis Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for gingivitis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of gingivitis drug candidates.

Drug: Chlorhexidine Toothpaste

Chlorhexidine Toothpaste (0.3%), sponsored by Colgate-Palmolive, is being evaluated in a Phase III clinical study to assess its effectiveness in reducing gingival inflammation in patients with dental plaque and gingivitis. This randomized, double-blind trial involves around 80 participants aged 18-70 and is expected to be completed by April 2025.

Drug: Povidone-Iodine Solution

Povidone-iodine, a topical antiseptic known for its antimicrobial properties, is being investigated in a Phase II study conducted by the University of Washington. The study aims to assess the efficacy and safety of 10% Povidone-iodine in preventing white spot lesions and gingival inflammation in orthodontic patients aged 10-17. The study, involving approximately 80 participants, is expected to conclude by March 2027.

Drug: Ginger Mouthwash

Ginger mouthwash, known for its anti-inflammatory properties, is being investigated in a Phase II study sponsored by Al-Mustansiriyah University for its potential benefits in treating gingivitis in pregnant women under stress. The study aims to assess the effectiveness of ginger mouthwash in reducing gingival inflammation and lowering salivary biomarkers such as IL-6 and cortisol, which are indicators of inflammation and stress. The ginger mouthwash will be compared with chlorhexidine and a placebo to determine its relative efficacy. The study is expected to conclude by April 20, 2025, and is expected to enroll 51 participants.

Reasons To Buy This Report

The Gingivitis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for gingivitis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into gingivitis collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Gingivitis - Pipeline Insight Report

• Which companies/institutions are leading the gingivitis drug development?
• What is the efficacy and safety profile of gingivitis pipeline drugs?
• Which company is leading the gingivitis pipeline development activities?
• What is the current gingivitis commercial assessment?
• What are the opportunities and challenges present in the gingivitis drug pipeline landscape?
• What is the efficacy and safety profile of gingivitis pipeline drugs?
• Which company is conducting major trials for gingivitis drugs?
• Which companies/institutions are involved in gingivitis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in gingivitis?

This product will be delivered within 3-5 business days.